From what 7 stock analysts predict, the share price for Hologic Inc (HOLX) might increase by 11.68% in the next year. This is based on a 12-month average estimation for HOLX. Price targets go from $76.00 to $90.00. The majority of stock analysts believe HOLX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Hologic Inc has a total of 7 Wall St Analyst ratings. There are 3 buy ratings, 4 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Hologic Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
michael matson Needham | Buy | $90.0 | maintained | Feb 7, 2024 |
anthony petrone Mizuho Securities | Buy | $85.0 | maintained | Feb 2, 2024 |
puneet souda Leerink Partners | Buy | $90.0 | maintained | Feb 1, 2024 |
david toung Argus Research | Buy | $89.0 | maintained | Jan 23, 2024 |
casey woodring J.P. Morgan | Buy | $85.0 | maintained | Nov 10, 2023 |
andrew cooper Raymond James | Buy | $85.0 | maintained | Oct 18, 2023 |
jayson bedford Raymond James | Buy | $95.0 | maintained | Aug 1, 2023 |
max masucci Cowen & Co. | Buy | $95.0 | maintained | Feb 2, 2023 |
navann ty Exane BNP Paribas | Buy | $86.0 | initiatedcoverage | Dec 8, 2022 |
tycho peterson J.P. Morgan | Buy | $95.0 | maintained | Feb 3, 2022 |
dan leonard Credit Suisse | Buy | $90.0 | maintained | Feb 3, 2022 |
richard newitter Truist Financial | Buy | $85.0 | rated | Jul 29, 2021 |
raj denhoy Jefferies | Buy | $110.0 | maintained | Apr 5, 2021 |
doug schenkel Cowen & Co. | Buy | $64.0 | upgraded | Jun 30, 2020 |
brian weinstein William Blair | Buy | None | reiterated | Nov 21, 2019 |
ivy ma Bank of America Securities | Buy | $59.0 | upgraded | Sep 26, 2019 |
isaac ro Goldman Sachs | Buy | $43.0 | maintained | Apr 17, 2018 |
sara wojda Gabelli | Buy | None | initiatedcoverage | Dec 15, 2016 |
jon groberg UBS | Buy | $45.0 | reiterated | Oct 28, 2016 |
dalton chandler Needham | Buy | $22.0 | reiterated | Jul 31, 2012 |
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
When did it IPO
1990
Staff Count
6,990
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Mr. Stephen P. MacMillan
Market Cap
$17.32B
In 2023, HOLX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that HOLX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
ENPH-USD
$126.24
$11.95
CINF-USD
$111.25
NTAP-USD
$85.71
$117.9
FSLR-USD
$150.03